Dr. Giada Bianchi, MD

Dr. Bianchi practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Bianchi's NPI, 1093945396, was assigned on July 21, 2009. Dr. Bianchi holds Massachusetts license 250662.

Dr. Bianchi's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Bianchi's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Bianchi is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Physicians Organization (MGPO). Dmand AI also links Dr. Bianchi to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bianchi practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Bianchi's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Bianchi is board certified in hematology by the American Board of Internal Medicine. Dr. Bianchi is licensed in Massachusetts.

CMS data shows 154 Medicare services from Dr. Bianchi across 4 procedure codes in 2024, for 85 Medicare patients. Medicare paid $13,477 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 85 Medicare patients who saw Dr. Bianchi in 2024. The largest group is 65 to 74, with 39 patients. 73% of them have high cholesterol, and 68% have high blood pressure. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bianchi's median patient age at 71, with 43% women.

In 2024, Dr. Bianchi wrote 38 Medicare Part D claims for 14 patients. 92% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $270 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

Dr. Bianchi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bianchi as offering telehealth.

Dmand AI links Dr. Bianchi to 1 clinical trial. Conditions studied include Multiple Myeloma and Blood Protein Disorders. Open Payments lists research payments to Dr. Bianchi that name 1 trial.

CMS Open Payments shows 33 general payments to Dr. Bianchi from 8 drug and device companies from 2018 to 2020. Consulting fees make up the largest share, 49% of the total. Celgene Corporation paid the most, $9,922. It also lists 1 research payment totaling $1,250 in 2021, naming 1 clinical trial.